AUG 5·SEC EDGARLow
Young Richard A purchased $27K of CAMP
Young Richard A purchased 16,378 shares of Camp4 Therapeutics Corp (CAMP) at $1.65 on 2026-08-03.
StockNASDAQ · US · USDHealthcare · Biotechnology
$CAMP
Camp4 Therapeutics Corp
Price · $CAMPvia TradingView
AI sentiment · 7d2 articles
- Bullish
- 1
- Neutral
- 1
- Bearish
- 0
Top stories · $CAMPMore →
AUG 5·SEC EDGAR
Maricich Yuri purchased $11K of CAMP
Maricich Yuri (Chief Medical Officer) purchased 6,551 shares of Camp4 Therapeutics Corp (CAMP) at $1.65 on 2026-08-03.
AUG 5·SEC EDGAR
Gold Kelly purchased $11K of CAMP
Gold Kelly (Chief Financial Officer) purchased 6,551 shares of Camp4 Therapeutics Corp (CAMP) at $1.65 on 2026-08-03.
CAMP sentiment & insider activity
Over the past 7 days, alphai's AI scored 2 news stories mentioning CAMP (Camp4 Therapeutics Corp). Coverage has skewed bullish: 1 bullish, 1 neutral, and 0 bearish.
Recent CAMP coverage spans insider activity, financial news and corporate actions.
In the last 30 days, CAMP insiders filed 4 SEC Form 4 transactions — 4 purchases ($59K) and no sales. The most active reporter was Young Richard A with 1 filing.
What's driving CAMP
The filing is a modest insider open-market purchase that may be read as confidence, but it is unlikely to be a standalone driver of fundamentals.
The filing is a routine insider open-market purchase with no stated new company fundamentals.
This is an insider buy, but it is a relatively small, non-10b5-1-plan transaction, so it is more sentiment than a fundamental catalyst.
This is a routine insider open-market purchase with no new operational or financial catalyst disclosed.
The filing discloses completion of the second closing in CAMP’s prior private placement, adding gross proceeds and increasing potential dilution via warrants.
alphai scores every news story that mentions CAMP with an AI model for sentiment and relevance, and aggregates insider trades from Camp4 Therapeutics Corp's SEC EDGAR Form 4 filings. Figures refresh continuously.
News on $CAMP
Score
Young Richard A purchased $27K of CAMP
Young Richard A purchased 16,378 shares of Camp4 Therapeutics Corp (CAMP) at $1.65 on 2026-08-03.
2 min readMaricich Yuri purchased $11K of CAMP
Maricich Yuri (Chief Medical Officer) purchased 6,551 shares of Camp4 Therapeutics Corp (CAMP) at $1.65 on 2026-08-03.
2 min readGold Kelly purchased $11K of CAMP
Gold Kelly (Chief Financial Officer) purchased 6,551 shares of Camp4 Therapeutics Corp (CAMP) at $1.65 on 2026-08-03.
1 min readMandel-Brehm Josh purchased $11K of CAMP
Mandel-Brehm Josh (Chief Executive Officer) purchased 6,551 shares of Camp4 Therapeutics Corp (CAMP) at $1.65 on 2026-08-03.
2 min readCamp4 Therapeutics Corp (CAMP): Entry into a Material Definitive Agreement
Camp4 Therapeutics Corp (CAMP) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. camp-20260803 0001736730 false 0001736730 2026-08-03 2026-08-03 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported):
4 min read
Top Biotech Gainers: UPC Cuts Loss, CPIX Gains Ahead Of Q2 Results, AUTL Builds Commercial Momentum
Biotech gainers on Monday included Universe Pharmaceuticals (UPC), which reported six-month ended March 31, 2026 revenue of $9.03 million and net loss of $1.55 million, and shares rose about 99% to $6.48. Cumberland Pharma (CPIX) rose over 38% ahead of Q2 results after a $100 million branded portfolio sale. Autolus (AUTL) gained about 22% on preliminary Q2 Aucatzyl net product revenue of about $45 million. Other movers included Pulmonx (LUNG), SL Science (SLBT), CAMP4 (CAMP), and Beyond Air (XAI
3 min readCamp4 Therapeutics Corp (CAMP): Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
Camp4 Therapeutics Corp (CAMP) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. EX-10.2 3 exhibit102-camp4therapeuti.htm EX-10.2 Document Exhibit 10.2 CAMP4 THERAPEUTICS CORPORATION 2026 INDUCEMENT PLAN 1. DEFINED TERMS Exhibit A , which is incorporated by reference, defines certain terms used in the Plan and includes certain operational rules related to tho
3 min read
CAMP4 Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
CAMP4 Therapeutics announced a non-qualified stock option grant for 5,000 shares to a new employee as an inducement, in accordance with Nasdaq Listing Rule 5635(c)(4). The grant, with an exercise price of $4.31, vests over four years, aligning with the company's biopharmaceutical focus on developing regulatory RNA-targeting therapeutics.
2 min read
CAMP4 Therapeutics Corporation (NASDAQ:CAMP) Short Interest Down 14.2% in March
CAMP4 Therapeutics Corporation (NASDAQ:CAMP) experienced a 14.2% decrease in short interest during March, settling at 414,235 shares, representing about 1.2% of its outstanding shares. Despite this, the company reported disappointing quarterly earnings, missing analyst consensus with an EPS of ($0.87) against an expected ($0.31). Analysts maintain a "Moderate Buy" rating with an average target price of $8.60, even as the company faces significant profitability challenges.
4 min readCAMP4 Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635 (c) (4)
CAMBRIDGE, Mass., Nov. 14, 2025 ( GLOBE NEWSWIRE ) -- CAMP4 Therapeutics Corporation ( "CAMP4" or "the Company" ) ( Nasdaq: CAMP ) , a clinical-stage biopharmaceutical company developing a pipeline of regulatory RNA-targeting therapeutics designed to upregulate gene expression with the goal of ...
2 min read